LIFT AD

20 Apr LIFT AD

To evaluate the clinical efficacy of ATH-1017
To determine the safety and tolerability of ATH-1017
To evaluate the clinical efficacy of ATH-1017 separately on:
(1) cognition and
(2) clinical global impression of change
To evaluate the effect of ATH-1017 on activities of daily living
To determine the plasma pharmacokinetic (PK) profile of ATH-1017
To evaluate the effect of ATH-1017 on behavioral changes
To evaluate the effect of ATH-1017 on overall cognitive function
To evaluate the effect of ATH-1017 on executive memory function
To evaluate any effect of ATH-1017 on:
(1) caregiver burden
(2) healthcare resource utilization
(3) subject health-related quality of life

This is a Phase 2 study

Participant Eligibility

Males and females age 55 to 85, inclusive at time of signing informed consent
Mild to moderate AD dementia
Clinical diagnosis of dementia, due probably to AD
Documented clinical decline within 12 months of evaluation
Onset of symptoms at least 12 months before evaluation – preferably participant's medical records but caregiver reports with examples are acceptable
Reliable and capable support person/caregiver who is willing to accept responsibility for supervising the treatment or, if required, administering study drug and assessing the condition of participant throughout the study
Support person/caregiver must see participant at least once daily for dose administration and/or observation and have 4-6 hours of daytime contact with participant at least 4 days per week

Contact

enroll
(142) 545-3040 x4